RAS 野生型转移性结直肠癌的一线治疗选择
RAS 야생형전이성결직장암적일선치료선택
The choice of first line therapy for RAS wild type metastatic colorectal cancer
  • 万方数据
    中华结直肠疾病电子杂志 중화결직장질병전자잡지
    Chinese Journal of Colorectal Diseases
    2015年 4期 24-28 ,共5页

    罗聪%应杰儿

    라총%응걸인

    结直肠肿瘤%肿瘤转移%一线治疗 結直腸腫瘤%腫瘤轉移%一線治療
    결직장종류%종류전이%일선치료
    Colorectal neoplasms%Neoplasm metastasis%First line therapy
    近年来新的化疗药物及靶向治疗药物极大地提高了转移性结直肠癌的疗效，但目前mCRC靶向药物的一线治疗选择尚不明确，本文就目前相关临床试验数据进行综合分析。
    근년래신적화료약물급파향치료약물겁대지제고료전이성결직장암적료효，단목전mCRC파향약물적일선치료선택상불명학，본문취목전상관림상시험수거진행종합분석。
    The introduction of new chemotherapeutics and monoclonal antibodies into the treatment protocols for advanced CRC has significantly improved the outcomes .Oncologists have a wide range of agents to choose for the treatment of advanced CRC;however , their optimal administration remains unclear .This article presents recent data from the trials evaluating the use of monoclonal antibodies in advanced CRC .
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문